+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07222761

Comparing Linvoseltamab Alone and with Carfilzomib to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma

Led by Regeneron Pharmaceuticals · Updated on 2026-11-04

915

Participants Needed

53

Research Sites

274 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying linvoseltamab, either alone or combined with carfilzomib, compared to standard treatments for adults with relapsed or refractory multiple myeloma who have had one to three prior therapies. The purpose is to evaluate whether these treatments can provide deeper and longer-lasting responses and improve outcomes, while also examining safety and side effects. Participants will receive either linvoseltamab alone, linvoseltamab with carfilzomib, or one of several standard treatment combinations. The study is designed as an open-label, randomized trial where treatments are given according to protocol. The study may last up to several years to collect comprehensive data on treatment effects and side effects. During the trial, participants will undergo regular assessments including monitoring for adverse events, blood tests to measure drug levels and immune response, and evaluations of disease progression and quality of life. Researchers will measure outcomes such as treatment safety, disease response, survival, and patient-reported well-being over a follow-up period that can last up to five years after starting treatment.

CONDITIONS

Brief Title

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here